Johnson & Johnson vs Pfizer
Add, change or remove companies; up to four.
KIRA’s take AI analyst
I put Johnson & Johnson and Pfizer side by side, using each one’s latest annual report. Here is what stands out:
- Johnson & Johnson is the larger business, with $94.2B of revenue in fiscal 2025 against $62.6B for Pfizer, about 1.5 times as much.
- Johnson & Johnson grew revenue faster (6.1%, against −1.7%).
- Johnson & Johnson turned more of its sales into free cash flow (20.9% FCF margin, against 14.5%).
- Johnson & Johnson earned a higher return on the capital invested in it (28.6%, against 7.3%).
- Investors pay more for each dollar of Johnson & Johnson’s earnings: a P/E of 40.4x against 39.2x for Pfizer.
Who comes out ahead
Of the 10 measures where higher (or lower) is clearly better, how many each company leads.
Johnson & Johnson
JNJ
7/10
Revenue growthNet marginFCF marginReturn on capitalReturn on equityNet debt / EBITDAShare count change
Pfizer
PFE
3/10
5-year growthGross marginPiotroski F-score
Side by side
Best in the row
| Latest fiscal year | JNJ FY25 | PFE FY25 |
|---|---|---|
| Size | ||
| Market cap | $652.1B | $169.8B |
| Revenue | $94.2B | $62.6B |
| Free cash flow | $19.7B | $9.1B |
| Net income | $26.8B | $7.8B |
| Growth | ||
| Revenue growth | 6.1% | −1.7% |
| 5-year growth | 2.7% | 8.5% |
| Share count change | 0.0% | 0.2% |
| Profitability | ||
| Gross margin | 67.9% | 74.3% |
| Operating margin | — | — |
| Net margin | 28.5% | 12.4% |
| FCF margin | 20.9% | 14.5% |
| Return on capital | 28.6% | 7.3% |
| Return on equity | 35.0% | 8.9% |
| Balance sheet | ||
| Net debt | $27.8B | $54.3B |
| Net debt / EBITDA | 0.7x | 3.2x |
| Dividends and buybacks | $18.3B | $9.8B |
| Valuation & quality | ||
| P/E | 40.4x | 39.2x |
| Piotroski F-score | 4 | 6 |
Ten years
Revenue
Operating margin
Free cash flow
Return on capital
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.